320 related articles for article (PubMed ID: 6997738)
21. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report.
Szmuness W; Stevens CE; Zang EA; Harley EJ; Kellner A
Hepatology; 1981; 1(5):377-85. PubMed ID: 7030902
[TBL] [Abstract][Full Text] [Related]
22. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy.
Samandari T; Fiore AE; Negus S; Williams JL; Kuhnert W; McMahon BJ; Bell BP
Pediatrics; 2007 Aug; 120(2):e373-81. PubMed ID: 17636112
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis B vaccine: clinical trials in high-risk settings in France. (September 1975-September 1982).
Goudeau A; Dubois F; Barin F; Dubois MC; Coursaget P
Dev Biol Stand; 1983; 54():267-84. PubMed ID: 6228468
[TBL] [Abstract][Full Text] [Related]
24. Persistence of vaccine-induced antibodies to hepatitis B surface antigen and the need for booster vaccination in adult subjects.
Ambrosch F; Frisch-Niggemeyer W; Kremsner P; Kunz C; André F; Safary A; Wiedermann G
Postgrad Med J; 1987; 63 Suppl 2():129-35. PubMed ID: 3317348
[TBL] [Abstract][Full Text] [Related]
25. [Efficacy and immune memory of plasma-derived hepatitis B vaccine 11 years after primary immunization].
Xu H; Zhuang G; Wang X; Chen Q; Chen Z
Zhonghua Yu Fang Yi Xue Za Zhi; 2000 Mar; 34(2):113-5. PubMed ID: 11860915
[TBL] [Abstract][Full Text] [Related]
26. Reactogenicity and immunogenicity of a recombinant hepatitis B vaccine compared with a plasma-derived vaccine in young adults.
Just M; Berger R; Just V
Postgrad Med J; 1987; 63 Suppl 2():121-3. PubMed ID: 3317346
[TBL] [Abstract][Full Text] [Related]
27. Antibody titration and immune response of Iranian beta-thalassemic patients to hepatitis B virus vaccine (booster effect).
Azarkeivan A; Karimi G; Shaiegan M; Maghsudlu M; Tabbaroki A
Pediatr Hematol Oncol; 2009 Jun; 26(4):195-201. PubMed ID: 19437322
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity of a yeast-derived hepatitis B vaccine (Engerix-B) in healthy young adults.
Crovari P; Crovari PC; Petrilli RC; Icardi GC; Bonanni P
Postgrad Med J; 1987; 63 Suppl 2():161-4. PubMed ID: 3317356
[TBL] [Abstract][Full Text] [Related]
29. [Long-term efficacy of plasma-derived hepatitis B vaccine among Chinese children--a 12-year follow-up].
Liao S; Li R; Li H; Yang J; Zeng X
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Apr; 20(2):89-94. PubMed ID: 11367725
[TBL] [Abstract][Full Text] [Related]
30. Adult hepatitis B vaccination using a novel triple antigen recombinant vaccine.
Young MD; Schneider DL; Zuckerman AJ; Du W; Dickson B; Maddrey WC;
Hepatology; 2001 Aug; 34(2):372-6. PubMed ID: 11481622
[TBL] [Abstract][Full Text] [Related]
31. A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine.
Dupont J; Altclas J; Lepetic A; Lombardo M; Vázquez V; Salgueira C; Seigelchifer M; Arndtz N; Antunez E; von Eschen K; Janowicz Z
Vaccine; 2006 Nov; 24(49-50):7167-74. PubMed ID: 16884836
[TBL] [Abstract][Full Text] [Related]
32. The protection of chimpanzees against hepatitis B viral infection using a recombinant yeast-derived hepatitis B surface antigen.
Schellekens H; de Reus A; Peetermans JH; van Eerd PA
Postgrad Med J; 1987; 63 Suppl 2():93-6. PubMed ID: 3317363
[TBL] [Abstract][Full Text] [Related]
33. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study.
Bialek SR; Bower WA; Novak R; Helgenberger L; Auerbach SB; Williams IT; Bell BP
Pediatr Infect Dis J; 2008 Oct; 27(10):881-5. PubMed ID: 18756185
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of a new hepatitis B triple-antigen vaccine in inadequate responders to current vaccines.
Zuckerman JN; Zuckerman AJ; Symington I; Du W; Williams A; Dickson B; Young MD;
Hepatology; 2001 Oct; 34(4 Pt 1):798-802. PubMed ID: 11584378
[TBL] [Abstract][Full Text] [Related]
35. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years.
Hammitt LL; Hennessy TW; Fiore AE; Zanis C; Hummel KB; Dunaway E; Bulkow L; McMahon BJ
Vaccine; 2007 Sep; 25(39-40):6958-64. PubMed ID: 17714836
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis B vaccine in developing countries: problems and prospects.
Ayoola EA
IARC Sci Publ; 1984; (63):297-305. PubMed ID: 6242148
[TBL] [Abstract][Full Text] [Related]
37. Intramuscular versus low-dose intradermal hepatitis B vaccine. Assessment by humoral and cellular immune response to hepatitis B surface antigen.
Frazer IH; Jones B; Dimitrakakis M; Mackay IR
Med J Aust; 1987 Mar; 146(5):242-5. PubMed ID: 2950303
[TBL] [Abstract][Full Text] [Related]
38. A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army.
Seeff LB; Beebe GW; Hoofnagle JH; Norman JE; Buskell-Bales Z; Waggoner JG; Kaplowitz N; Koff RS; Petrini JL; Schiff ER
N Engl J Med; 1987 Apr; 316(16):965-70. PubMed ID: 2436048
[TBL] [Abstract][Full Text] [Related]
39. Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in french haemodialysis units: II, Haemodialysis patients.
Crosnier J; Jungers P; Couroucé AM; Laplanche A; Benhamou E; Degos F; Lacour B; Prunet P; Cerisier Y; Guesry P
Lancet; 1981 Apr; 1(8224):797-800. PubMed ID: 6111671
[TBL] [Abstract][Full Text] [Related]
40. Hepatitis B vaccine in health care personnel: safety, immunogenicity, and indicators of efficacy.
Dienstag JL; Werner BG; Polk BF; Snydman DR; Craven DE; Platt R; Crumpacker CS; Ouellet-Hellstrom R; Grady GF
Ann Intern Med; 1984 Jul; 101(1):34-40. PubMed ID: 6233921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
